Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.71 |
| ▸ | TEK | Q02763 | 10/20 | 0.71 |
| ▸ | LCK | P06239 | 7/20 | 0.71 |
| ▸ | SRC | P12931 | 4/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 4/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020100 | 0.89 | KDR (0.68) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL2074398 | 0.89 | PIK3CD (0.73) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL2074335 | 0.87 | KDR (0.76) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL7009436 | 0.86 | KDR (0.55) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL2074938 | 0.85 | KDR (0.64) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL29780906 | 0.85 | RET (0.56) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL23170598 | 0.83 | KDR (0.67) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL7005359 | 0.83 | TEK (1.00) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL29552512 | 0.83 | TEK (1.00) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL29052163 | 0.83 | KDR (0.52) | KDRTEKLCKSRCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287081-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-08-29 | — | — | US | disclosed |
| CN-111689991-B | Substituted heteroaryl compounds, compositions and uses thereof | 习峰 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022261352-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261352-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-110627796-B | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-110036014-B | Compound with AXL inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2021-09-07 | — | — | CN | disclosed |
| CN-111689991-A | Substituted heteroaryl compounds, compositions and uses thereof | 习峰 | 2020-09-22 | — | — | CN | disclosed |
| WO-2020182188-A1 | SUBSTITUTED HETEROARYL COMPOUND, COMPOSITION OF SAME, AND USES THEREOF | 习峰 | 2020-09-17 | — | — | WO | disclosed |
| CN-110627796-A | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| WO-2018121228-A1 | COMPOUND HAVING AXL INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2018-07-05 | — | — | WO | disclosed |
| CN-1134439-C | Pyrrolo [2,3D ] pyrimidines and their use as tyrosine kinase inhibitors | 艾博特股份有限两合公司 | 2004-01-14 | — | — | CN | disclosed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-0970084-A1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | disclosed |
| US-6001839-A | Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | disclosed |
| WO-1998041525-A1 | PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287081-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | PPARD, PFAS, FOLR2 | KDR 300/4885TEK 605/4885LCK 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.